shine-logo

SHINE announces first sales of n.c.a. Lu-177

SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.

2021-12-17T17:38:58-06:00November 4, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|

SHINE & IOCB deliver Lu-177 doses to GE

SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).

2021-12-16T20:07:30-06:00January 21, 2020|2020, Medical Isotopes, News, News Releases, Therapeutics|

SHINE Creates Therapeutics Division

SHINE Medical Technologies today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.

2021-12-17T17:41:45-06:00October 11, 2019|2019, Archived, Medical Isotopes, News Releases|

SHINE Licenses Lu-177 Separation Process

SHINE Medical Technologies and Institute of Organic Chemistry and Biochemistry of the CAS have entered into an intellectual property license agreement providing SHINE with a global, exclusive license to a novel method for separating rare earth elements.  SHINE will use the innovation to produce lutetium-177 (Lu-177) for the treatment of cancer.

2021-12-17T17:45:41-06:00May 15, 2019|2019, Archived, Medical Isotopes, News Releases|
Go to Top